{"protocolSection": {"identificationModule": {"nctId": "NCT00964678", "orgStudyIdInfo": {"id": "HM12120"}, "organization": {"fullName": "Virginia Commonwealth University", "class": "OTHER"}, "briefTitle": "Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension", "officialTitle": "Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension"}, "statusModule": {"statusVerifiedDate": "2017-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-06"}, "primaryCompletionDateStruct": {"date": "2014-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-08-24", "studyFirstSubmitQcDate": "2009-08-24", "studyFirstPostDateStruct": {"date": "2009-08-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-12-10", "resultsFirstSubmitQcDate": "2017-06-06", "resultsFirstPostDateStruct": {"date": "2017-06-08", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-06-06", "lastUpdatePostDateStruct": {"date": "2017-06-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Virginia Commonwealth University", "class": "OTHER"}, "collaborators": [{"name": "GlaxoSmithKline", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether carvedilol treatment of patients with pulmonary arterial hypertension and associated right heart failure is safe and results in an improved function of the right heart.", "detailedDescription": "Patients with pulmonary arterial hypertension (PAH) will be treated with carvedilol for 24 weeks. During this time, carvedilol will be titrated from an initial dose of 3.125mg BID to a maximal dose of 25mg BID. At the start and end of the study, we will obtain cardiac MRI, 6 minute walk distance, brain natriuretic peptide (serum), echocardiogram, and functional class assessment. Our primary outcome is a change in right ventricular ejection fraction with cardiac MRI."}, "conditionsModule": {"conditions": ["Pulmonary Arterial Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 10, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "carvedilol", "type": "EXPERIMENTAL", "description": "Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI", "interventionNames": ["Drug: Carvedilol"]}], "interventions": [{"type": "DRUG", "name": "Carvedilol", "description": "twice daily oral treatment in escalating dose", "armGroupLabels": ["carvedilol"], "otherNames": ["Coreg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Absolute Change in Right Ventricular Ejection Fraction", "description": "Change in right ventricular ejection fraction is measured by cardiac magnetic resonance imaging, using the method of disks with the reading radiologist being blinded to before and after images. Cardiac magnetic resonance imaging was done at baseline and 6 months only", "timeFrame": "baseline, 6 months"}], "secondaryOutcomes": [{"measure": "Change in Right Ventricular End Systolic Volume", "description": "right ventricular end systolic volume determined by MRI", "timeFrame": "baseline and 6 months"}, {"measure": "Change in 6 Minute Walk Distance", "timeFrame": "baseline and 6 months"}, {"measure": "Change in Tricuspid Annular Plane Systolic Excursion", "description": "Higher values indicate a better outcome.", "timeFrame": "baseline and 6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* idiopathic, familial or associated PAH, WHO group 1\n* NYHA class II or III\n* clinically stable with optimized PAH treatment for at least 3 months\n* no or minimal evidence of fluid overload or volume depletion, with or without diuretic treatment\n* age \\> 18 years\n* mean pulmonary artery pressure (mPAP) \\> 25 mmHg\n* 6 minute walk distance (6MWD) over 100m\n\nExclusion Criteria:\n\n* Structural heart disease unrelated to PAH\n* Recent (\\<3 months) treatment with an intravenous positive inotropic agent\n* current use of \u03b2-blockers\n* history of reactive airways disease\n* history of adverse reaction to \u03b2-blockers\n* heart block on ECG or resting heart rate \\< 60 bpm\n* cardiac index \\< 1.8 l/min/m2\n* systemic hypotension (systolic pressure \\< 90 mmHg)\n* pulmonary capillary wedge pressure \\> 15 mmHg\n* inability to give informed consent\n* contraindications to CT and/or PET scanning\n* coagulopathy (INR\\>1.5 or platelet count\\<50000/mm3)\n* severe renal insufficiency (creatinine clearance \\<30 ml/min/m2)\n* malignancy or any co-morbidity limiting survival or conditions predicting inability to complete the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Daniel C Grinnan, M.D", "affiliation": "Virginia Commonwealth University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Virginia Commonwealth University", "city": "Richmond", "state": "Virginia", "zip": "23298", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}]}, "referencesModule": {"references": [{"pmid": "24930531", "type": "DERIVED", "citation": "Grinnan D, Bogaard HJ, Grizzard J, Van Tassell B, Abbate A, DeWilde C, Priday A, Voelkel NF. Treatment of group I pulmonary arterial hypertension with carvedilol is safe. Am J Respir Crit Care Med. 2014 Jun 15;189(12):1562-4. doi: 10.1164/rccm.201311-2025LE. No abstract available."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "IPD will not be shared"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Carvedilol", "description": "Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Patients had pulmonary arterial hypertension, on pulmonary vasodilator therapy at baseline", "groups": [{"id": "BG000", "title": "Carvedilol", "description": "Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI\n\nCarvedilol: twice daily oral treatment in escalating dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "6"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "4"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "2"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "60.6", "lowerLimit": "49", "upperLimit": "73"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "2"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}]}]}]}, {"title": "Right ventricular ejection fraction of blood", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "% of ejected ventricular vol of blood", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "38", "lowerLimit": "19", "upperLimit": "56"}]}]}]}, {"title": "Six minute walk distance", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "meters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "321", "lowerLimit": "292", "upperLimit": "559"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Absolute Change in Right Ventricular Ejection Fraction", "description": "Change in right ventricular ejection fraction is measured by cardiac magnetic resonance imaging, using the method of disks with the reading radiologist being blinded to before and after images. Cardiac magnetic resonance imaging was done at baseline and 6 months only", "populationDescription": "Patients with right heart catheterization confirmed pulmonary arterial hypertension, already on pulmonary vasodilator therapy", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "% RVEF", "timeFrame": "baseline, 6 months", "groups": [{"id": "OG000", "title": "Carvedilol", "description": "Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI\n\nCarvedilol: twice daily oral treatment in escalating dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.4", "lowerLimit": "3.6", "upperLimit": "16"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.028", "pValueComment": "The threshold for statistical significance was p=0.05.", "statisticalMethod": "ANOVA", "ciPctValue": "20", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Change in Right Ventricular End Systolic Volume", "description": "right ventricular end systolic volume determined by MRI", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "mL", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "Carvedilol", "description": "Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "classes": [{"title": "Participant 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Participant 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}]}]}, {"title": "Participant 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "56"}]}]}, {"title": "Participant 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}]}]}, {"title": "Participant 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}]}]}, {"title": "Participant 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.028", "pValueComment": "The threshold for statistical significance was p=0.05.", "statisticalMethod": "ANOVA"}]}, {"type": "SECONDARY", "title": "Change in 6 Minute Walk Distance", "populationDescription": "The patient who was excluded from analysis developed an orthopedic injury during the study and was unable to complete the walking test at conclusion of the study", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "feet", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "Carvedilol", "description": "Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "classes": [{"title": "Participant 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}]}]}, {"title": "Participant 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "160"}]}]}, {"title": "Participant 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "35"}]}]}, {"title": "Participant 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}]}]}, {"title": "Participant 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "96"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY", "pValue": ">0.05", "pValueComment": "The threshold for statistical significance was p=0.05.", "statisticalMethod": "ANOVA", "ciPctValue": "20", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Change in Tricuspid Annular Plane Systolic Excursion", "description": "Higher values indicate a better outcome.", "populationDescription": "The patient excluded from the analysis was unable to be present for the final echo-cardiogram due to lack of transportation and distance from the hospital. Multiple attempts to schedule the study test were made through phone and email.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "centimeters", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "Carvedilol", "description": "Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI\n\nCarvedilol: twice daily oral treatment in escalating dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "classes": [{"title": "Participant 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4"}]}]}, {"title": "Participant 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.08"}]}]}, {"title": "Participant 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.12"}]}]}, {"title": "Participant 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.45"}]}]}, {"title": "Participant 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.08"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY", "pValue": ">0.05", "statisticalMethod": "ANOVA", "ciPctValue": "20", "ciNumSides": "TWO_SIDED"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "6 months", "eventGroups": [{"id": "EG000", "title": "Carvedilol", "description": "Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI\n\nCarvedilol: twice daily oral treatment in escalating dose", "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 1, "otherNumAtRisk": 6}], "otherEvents": [{"term": "fatigue", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "mild, resolved with dose reduction and slow rate of titration", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "hypotension", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "asymptomatic. Mild, resolved with dose reduction", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Small number of patients enrolled. This study is hypothesis generating and was meant to lead to larger studies of carvedilol in pulmonary hypertension"}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dan Grinnan, MD", "organization": "Virginia Commonwealth University Health System", "email": "daniel.grinnan@vcuhealth.org", "phone": "804-828-9000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000081029", "term": "Pulmonary Arterial Hypertension"}, {"id": "D000065627", "term": "Familial Primary Pulmonary Hypertension"}, {"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006976", "term": "Hypertension, Pulmonary"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}], "browseLeaves": [{"id": "M2261", "name": "Pulmonary Arterial Hypertension", "asFound": "Pulmonary Arterial Hypertension", "relevance": "HIGH"}, {"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M10027", "name": "Hypertension, Pulmonary", "relevance": "LOW"}, {"id": "M30541", "name": "Familial Primary Pulmonary Hypertension", "asFound": "Pulmonary Arterial Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "T4807", "name": "Pulmonary Arterial Hypertension", "asFound": "Pulmonary Arterial Hypertension", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077261", "term": "Carvedilol"}], "ancestors": [{"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058668", "term": "Adrenergic alpha-1 Receptor Antagonists"}, {"id": "D000000317", "term": "Adrenergic alpha-Antagonists"}], "browseLeaves": [{"id": "M1718", "name": "Carvedilol", "asFound": "Depressive Disorder", "relevance": "HIGH"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M29194", "name": "Adrenergic alpha-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3669", "name": "Adrenergic alpha-Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}